You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)

Article metrics

Article menu
Download PDFPDF
Poster Presentation
SLE, Sjögren’s and APS - treatment
THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)

 

Online download statistics by month:

Online download statistics by month: February 2014 to March 2024

AbstractFullPdf
Feb 2014301
Mar 2014700
Apr 2014701
May 2014500
Jun 2014300
Jul 2014601
Oct 2014601
Nov 20141000
Dec 2014300
Jan 2015200
Feb 2015300
Mar 2015601
Apr 2015500
May 2015100
Jun 2015100
Jul 2015500
Aug 2015700
Sep 20151100
Oct 2015500
Nov 2015302
Dec 2015500
Jan 2016200
Feb 2016400
Mar 2016300
Apr 2016200
May 2016100
Jun 2016300
Jul 2016300
Aug 2016300
Sep 2016500
Oct 2016500
Nov 2016300
Dec 2016300
Jan 2017401
Feb 2017100
Mar 2017500
Apr 20171800
May 20171000
Jun 2017600
Jul 2017200
Aug 2017400
Sep 2017200
Oct 2017400
Nov 2017800
Dec 2017800
Jan 2018600
Feb 2018600
Mar 20181000
Apr 2018800
May 20182401
Jun 2018200
Jul 2018600
Aug 2018600
Sep 2018800
Nov 2018200
Dec 2018800
Jan 2019800
Feb 2019200
Mar 2019200
Apr 2019200
Dec 2019200
Feb 2020200
Jul 2020200
Sep 2020800
Nov 2020200
Dec 2020400
Jan 2021200
Oct 2021200
Dec 2021700
Feb 2022800
Mar 2022700
May 2022400
Jul 20221000
Sep 2022400
Oct 2022200
Nov 2022200
Dec 2022600
Feb 2023400
Mar 2023200
May 2023200
Jul 2023200
Aug 2023800
Sep 20231200
Dec 2023200
Jan 2024200
Feb 2024200
Mar 2024300
Total42609